Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of oral pharmaceutical composition for treating atherosclerosis

A technology of atherosclerosis and composition, applied in the field of medicine, can solve problems such as inconvenient drug taking, side effects, and complex ingredients of traditional Chinese medicine

Active Publication Date: 2018-07-24
淮北市宇控信息技术有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Simiao Yong'an Decoction (Honeysuckle, Scrophulariae, etc.), Xuefu Zhuyu Decoction (Peach Kernel, Safflower, Angelica, etc.), Yiqi Yangyin Recipe (Astragalus, Codonopsis, etc.), Rhubarb Zhechong Pills (cooked rhubarb, leeches, etc.) ), Danhong injection (Salvia miltiorrhiza, safflower, etc.), anti-stasis and phlegm-removing prescriptions (Gualou, Xiebai, etc.), also have anti-atherosclerotic effects, but due to the extremely complex ingredients of traditional Chinese medicine, it is difficult to determine the exact ingredients screening and verification
[0012] However, traditional Chinese medicine compound is slow to take effect in the treatment of atherosclerosis, it is inconvenient to take the medicine, and the quality of the medicine is difficult to control.
Chemical drugs such as antiplatelet drugs are often accompanied by obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of oral pharmaceutical composition for treating atherosclerosis
  • A kind of oral pharmaceutical composition for treating atherosclerosis
  • A kind of oral pharmaceutical composition for treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Granules for treating atherosclerosis and its preparation

[0037]

[0038] Preparation:

[0039] A: Take ligustrazine hydrochloride, disulfiram, primaquine, and rorapitant and pass through a 100-mesh sieve, and mix well.

[0040] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0041] The dosage of sugar is 2.0 times of the weight of ligustrazine hydrochloride; the dosage of microcrystalline cellulose is 1.2 times of the weight of ligustrazine hydrochloride; the dosage of crospovidone is 0.12 times of the weight of ligustrazine hydrochloride.

[0042] C: Mix the powder obtained in step A and step B evenly.

[0043] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.17 times of the weight of ligustrazine hydrochloride; the consumption of water is 32.3 times of the weight of povidone K30.

[0044] E: Th...

Embodiment 2

[0046] Example 2 Granules for treating atherosclerosis and its preparation

[0047]

[0048] Preparation:

[0049] A: Take ligustrazine hydrochloride, disulfiram, primaquine, and rorapitant and pass through a 100-mesh sieve, and mix well.

[0050] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0051] The amount is 2.0 times of the weight of ligustrazine hydrochloride; the amount of microcrystalline cellulose is 1.2 times of the weight of ligustrazine hydrochloride; the amount of crospovidone is 0.12 times of the weight of ligustrazine hydrochloride.

[0052] C: Mix the powder obtained in step A and step B evenly.

[0053] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.17 times of the weight of ligustrazine hydrochloride; the consumption of water is 32.3 times of the weight of povidone K30.

[0054] E: ...

Embodiment 3

[0056] Example 3 Granules for treating atherosclerosis and its preparation

[0057]

[0058] Preparation:

[0059] A: Take ligustrazine hydrochloride, disulfiram, primaquine, and rorapitant and pass through a 100-mesh sieve, and mix well.

[0060] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0061] The dosage of sugar is 2.0 times of the weight of ligustrazine hydrochloride; the dosage of microcrystalline cellulose is 1.2 times of the weight of ligustrazine hydrochloride; the dosage of crospovidone is 0.12 times of the weight of ligustrazine hydrochloride.

[0062] C: Mix the powder obtained in step A and step B evenly.

[0063] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.17 times of the weight of ligustrazine hydrochloride; the consumption of water is 32.3 times of the weight of povidone K30.

[0064] E: Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine and especially relates to an oral pharmaceutical composition for treating atherosclerosis. The oral pharmaceutical composition for treating atherosclerosis is prepared from pharmaceutically acceptable pharmaceutic adjuvants and 60-170 parts by weight of ligustrazine hydrochloride, 5-12 parts by weight of disulfiram, 1-7 parts by weight of primaquine and 1-3 parts by weight of Rolapitant. In the composition, Rolapitant can inhibit cardiovascular toxicity of disulfiram and primaquine and eliminate the phenomenon that efficacy is counteracted when disulfiram and primaquine are used in combination. The formula including ligustrazine hydrochloride, disulfiram, primaquine and Rolapitant has good antiatherosclerosis effect and safety.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to an oral pharmaceutical composition for treating atherosclerosis. Background technique [0002] Atherosclerosis (Atherosclerosis) is the lipid deposition in the intima and subintimal of the arterial wall, accompanied by the migration of smooth muscle cells in the middle layer to the subintimal hyperplasia, which thickens the intima and forms atherosclerotic plaques in cardiovascular and cerebrovascular diseases. disease. Atherosclerosis is one of the main diseases that endanger human health. The damage to cardiovascular and cerebrovascular can affect all major organs of the body, including heart, brain, kidney, etc., and is closely related to diabetes, hypertension, intracranial aneurysm, chronic ischemia It is closely related to the occurrence and development of sexual encephalopathy. A large-scale epidemiological survey of 700,000 people over the age of 35 in Beijing showed that the in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4965A61K31/145A61K31/4706A61K31/438A61P9/10
CPCA61K9/0053A61K31/145A61K31/438A61K31/4706A61K31/4965A61K47/38A61K2300/00
Inventor 朱会娟王全政孙振秋姚蕾王磊王金永
Owner 淮北市宇控信息技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com